BIOMEA FUSION INC. -

Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights

02 май 2023 15:01:20 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

01 май 2023 07:30:00 Источник Nasdaq GlobeNewswire

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June

19 апр 2023 07:30:00 Источник Nasdaq GlobeNewswire

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

13 апр 2023 15:30:00 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

13 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock

29 мар 2023 22:15:39 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces Proposed Public Offering of Common Stock

29 мар 2023 05:30:00 Источник Nasdaq GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

28 мар 2023 15:02:00 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28

28 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET

23 мар 2023 07:00:02 Источник Nasdaq GlobeNewswire

Biomea Fusion To Participate In Upcoming Investor Events

02 мар 2023 07:30:47 Источник Nasdaq GlobeNewswire

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

17 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones

09 янв 2023 07:00:02 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219

04 янв 2023 08:00:00 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

14 дек 2022 15:30:00 Источник Nasdaq GlobeNewswire

Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

12 дек 2022 07:00:01 Источник Nasdaq GlobeNewswire

Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference

11 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights

07 ноя 2022 15:27:31 Источник Nasdaq GlobeNewswire

Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting

03 ноя 2022 08:19:37 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

31 окт 2022 07:00:01 Источник Nasdaq GlobeNewswire